SEC Comment Letter for MESOBLAST (MESO) — Jan 5, 2026
MESOBLAST LTD
Date: Jan. 5, 2026 · CIK: 0001345099 · Accession: 0000000000-26-000045
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292498
Letter
Re: Mesoblast Limited Registration Statement on Form F-3 Filed December 30, 2025 File No. 333-292498 Dear Silviu Itescu:
January 5, 2026
Silviu Itescu Managing Director and Chief Executive Officer Mesoblast Limited Level 38, 55 Collins Street Melbourne, VIC 3000, Australia
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Andrew Reilly
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> January 5, 2026 Silviu Itescu Managing Director and Chief Executive Officer Mesoblast Limited Level 38, 55 Collins Street Melbourne, VIC 3000, Australia Re: Mesoblast Limited Registration Statement on Form F-3 Filed December 30, 2025 File No. 333-292498 Dear Silviu Itescu: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Andrew Reilly </TEXT> </DOCUMENT>